A new study shows that treatment with an immune-boosting protein called interleukin 7 (IL-7) in combination with radiation improves survival in mice with glioblastoma. The study in mice suggests promise for a phase 1/2 clinical trial that is investigating a long-acting type of IL-7 in patients with glioblastoma.